These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34872584)

  • 1. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
    Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
    Huang X; Zhang G; Tang T; Liang T
    Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
    Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
    Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
    Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
    Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
    Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
    Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
    Front Genet; 2022; 13():886983. PubMed ID: 35547260
    [No Abstract]   [Full Text] [Related]  

  • 11. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development.
    Wang F
    Clin Transl Oncol; 2023 Jul; 25(7):2204-2223. PubMed ID: 36781600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
    Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
    Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value and potential subtypes of immune activity scores in three major urological cancers.
    Shi B; Qi J
    J Cell Physiol; 2021 Apr; 236(4):2620-2630. PubMed ID: 32853461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the predictive value of angiogenesis-related genes for prognosis and immunotherapy response in prostate adenocarcinoma using machine learning and experimental approaches.
    Wang Y; He J; Zhao Q; Bo J; Zhou Y; Sun H; Ding B; Ren M
    Front Immunol; 2024; 15():1416914. PubMed ID: 38817605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines.
    Wang Y; Tan H; Yu T; Chen X; Jing F; Shi H
    Front Immunol; 2021; 12():755401. PubMed ID: 34917077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
    Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
    Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma.
    Zhao HB; Zeng YR; Han ZD; Zhuo YJ; Liang YK; Hon CT; Wan S; Wu S; Dahl D; Zhong WD; Wu CL
    Cancer Sci; 2021 Oct; 112(10):4365-4376. PubMed ID: 34252262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-cell and bulk RNA-sequencing reveals mitosis-involved gene HAUS1 is a promising indicator for predicting prognosis and immune responses in prostate adenocarcinoma (PRAD).
    Liu S; Yu Y; Xu J; Wang Y; Li D
    Cell Biol Int; 2024 Aug; 48(8):1169-1184. PubMed ID: 38818762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.